Australia’s Clinuvel Says Phase III Trial Of UV-Blocking Drug A Success
This article was originally published in PharmAsia News
Executive Summary
Australia's Clinuvel reports Phase III success for its afamelanotide drug for a rare genetic disorder that causes a skin intolerance to ultraviolet radiation and light. The trial, Clinuvel said, showed the EPP drug significantly reduced the severity of phototoxic reaction. It works by stimulating melanin production to absorb ultraviolet radiation. The trials were conducted in Switzerland and similar trials are expected to take place later this year in Europe and Australia. (Click here for more